share_log

Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target

Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target

Capital One将Outlook Therapeutics上调至增持,宣布5美元的
Benzinga ·  2023/12/27 08:58

Capital One analyst Zegbeh Jallah upgrades Outlook Therapeutics (NASDAQ:OTLK) from Equal-Weight to Overweight and announces $5 price target.

Capital One分析师泽格贝·贾拉将Outlook Therapeutics(纳斯达克股票代码:OTLK)从等重上调至增持,并宣布了5美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发